hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06370026, orgStudyIdInfo id: KSD-101-CR004, briefTitle: KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Sun Yat-sen University, class: OTHER, collaborators name: Kousai Bio Co., Ltd., descriptionModule briefSummary: The main purpse of this study is to evaluate the safety of KSD-101 in patients with EBV-associated Nasopharyngeal Carcinoma,to evaluate the initial clinical outcomes and evaluate the immune response to KSD-101 for the treatment in Patients with EBV-associated Nasopharyngeal Carcinoma., conditionsModule conditions: Nasopharyngeal Carcinoma, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: KSD-101, outcomesModule primaryOutcomes measure: The incidence Adverse events (Safety endpoint), secondaryOutcomes measure: EBV-DNA load, secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Levels of EBV-specific CD8+ T cells, secondaryOutcomes measure: Levels of B cells, secondaryOutcomes measure: Levels of NK cells, secondaryOutcomes measure: According to EORTC QLQ-C30, secondaryOutcomes measure: According to EQ-5D-5L, secondaryOutcomes measure: According to EORTC QLQ-H&N35, secondaryOutcomes measure: According to ECOG fitness status, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sun Yat-sen University Cancer Center, city: Guangzhou, state: Guangdong, zip: 510060, country: China, geoPoint lat: 23.11667, lon: 113.25, hasResults: False
protocolSection identificationModule nctId: NCT06370013, orgStudyIdInfo id: TT00420US14, briefTitle: Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors, statusModule overallStatus: AVAILABLE, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: TransThera Sciences (Nanjing), Inc., class: INDUSTRY, descriptionModule briefSummary: This study is an open-label, multicenter study for Continued Characterization of Safety and Tolerability of TT-00420 (tinengotinib) Tablet Monotherapy in Adult Patients with Advanced Solid Tumors, conditionsModule conditions: Advanced Solid Tumors, conditions: Cholangiocarcinoma, designModule studyType: EXPANDED_ACCESS, armsInterventionsModule interventions name: Tinengotinib, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Chicago Medical Center, status: AVAILABLE, city: Chicago, state: Illinois, zip: 60637, country: United States, geoPoint lat: 41.85003, lon: -87.65005, locations facility: Roswell Park Comprehensive Cancer Center, status: AVAILABLE, city: Buffalo, state: New York, zip: 14203, country: United States, geoPoint lat: 42.88645, lon: -78.87837, locations facility: Sarah Cannon Research Institute, status: AVAILABLE, city: Nashville, state: Tennessee, zip: 37203, country: United States, geoPoint lat: 36.16589, lon: -86.78444, locations facility: MD Anderson Cancer Center, status: AVAILABLE, city: Houston, state: Texas, zip: 77030, country: United States, geoPoint lat: 29.76328, lon: -95.36327, locations facility: UW Carbone Cancer Center, status: AVAILABLE, city: Madison, state: Wisconsin, zip: 53705, country: United States, geoPoint lat: 43.07305, lon: -89.40123, hasResults: False
protocolSection identificationModule nctId: NCT06370000, orgStudyIdInfo id: MCC-23-20817, secondaryIdInfos id: HM20029540, type: OTHER, domain: Virginia Commonwealth University, briefTitle: Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality, acronym: REMAIN1, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2026-10-31, completionDateStruct date: 2028-10-31, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Virginia Commonwealth University, class: OTHER, descriptionModule briefSummary: Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains, conditionsModule conditions: Acute Myeloid Leukemia, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Oral Azacitidine, outcomesModule primaryOutcomes measure: Rate of completion of at least 4 cycles an oral maintenance strategy for transplant eligible AML patients in CR who are medically underserved or have a disadvantage in the CDC SDOH domains, secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Leukemia Free Survival (LFS) 3 months after beginning of treatment and at relapse, completion of treatment or removal from study, secondaryOutcomes measure: Measure rates of measurable residual disease (MRD) negativity, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Virginia Commonwealth University, city: Richmond, state: Virginia, zip: 23298, country: United States, contacts name: Kristin Lantis, MSN, RN, role: CONTACT, phone: 804-828-2177, email: kllantis@vcu.edu, contacts name: Massey Heme Malig Team, role: CONTACT, email: MasseyHemMlg@vcu.edu, contacts name: Keri Maher, DO, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.55376, lon: -77.46026, hasResults: False
protocolSection identificationModule nctId: NCT06369987, orgStudyIdInfo id: 46238, briefTitle: Visual Performance of Dailies Total1 Multifocal and Acuvue Oasys Max 1-Day Multifocal in Presbyopic Lens Wearers, acronym: GIRAFFE, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-10, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: University of Waterloo, class: OTHER, collaborators name: Alcon Research, descriptionModule briefSummary: The purpose of this study is to measure the logMAR visual acuity when presbyopic soft lens wearers are fit with Dailies Total1 Multifocal and ACUVUE OASYS MAX 1-DAY Multifocal., conditionsModule conditions: Presbyopia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Deleficon A (multifocal), interventions name: Senofilcon A (multifocal), outcomesModule primaryOutcomes measure: High contrast visual acuity (logMAR) at 6m, primaryOutcomes measure: High contrast visual acuity (logMAR) at 40cm, eligibilityModule sex: ALL, minimumAge: 42 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Centre for Ocular Research & Education (CORE), city: Waterloo, state: Ontario, zip: N2L 3G1, country: Canada, contacts name: Jill Woods, MSc, MCOptom, role: CONTACT, phone: 519-888-4567, phoneExt: 36746, email: jwoods@uwaterloo.ca, contacts name: Lyndon Jones, PhD, FCOptom, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.4668, lon: -80.51639, hasResults: False
protocolSection identificationModule nctId: NCT06369974, orgStudyIdInfo id: 2024P000386, briefTitle: Single Participant Study of an Experimental ASO Treatment for TUBB4A-related Leukodystrophy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2026-06, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: Massachusetts General Hospital, class: OTHER, collaborators name: n-Lorem Foundation, descriptionModule briefSummary: This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single pediatric participant with TUBB4A associated leukodystrophy., conditionsModule conditions: Genetic Disease, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Single participant interventional study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, maskingDescription: Open label study, enrollmentInfo count: 1, type: ESTIMATED, armsInterventionsModule interventions name: Antisense oligonucleotide treatment (ASO), outcomesModule primaryOutcomes measure: Neurological assessments, secondaryOutcomes measure: Feeding and swallow evaluation, secondaryOutcomes measure: Safety and tolerability, eligibilityModule sex: ALL, minimumAge: 4 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06369961, orgStudyIdInfo id: TDFCANCERPAIN20230101, briefTitle: Correlation Between the Analgesic Effect of Fentanyl Transdermal Patches and Nutritional Status in Cancer Pain Patients, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-03-01, primaryCompletionDateStruct date: 2023-07-31, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Chongqing University Cancer Hospital, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to investigate the correlation and quantitative relationship between the analgesic effect of fentanyl transdermal patches in cancer pain patients and their nutritional status., conditionsModule conditions: Cancer Pain, conditions: Nutrition Disorders, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 151, type: ACTUAL, armsInterventionsModule interventions name: transdermal fentanyl, outcomesModule primaryOutcomes measure: 11-point numeric rating scale (NRS) after TDF treatment, primaryOutcomes measure: the occasions that breakthrough pain attacks per day after TDF treatment, primaryOutcomes measure: The dose adjustment of TDF, primaryOutcomes measure: The kinds of other analgesics combined with TDF, secondaryOutcomes measure: Adverse effects, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chao Li, city: Chongqing, zip: 400030, country: China, geoPoint lat: 29.56278, lon: 106.55278, hasResults: False
protocolSection identificationModule nctId: NCT06369935, orgStudyIdInfo id: 20240407, briefTitle: A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-20, primaryCompletionDateStruct date: 2026-08-20, completionDateStruct date: 2027-08-20, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Peking University People's Hospital, class: OTHER, descriptionModule briefSummary: This study is a multicenter, observational, single-arm real world study. The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in China with relapsed/refractory multiple myeloma (RRMM) who have been treated with Equecabtagene Autoleucel. This study will use both prospective and retrospective data, conditionsModule conditions: Relapsed/Refractory Multiple Myeloma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 260, type: ESTIMATED, armsInterventionsModule interventions name: Equecabtagene Autoleucel, outcomesModule primaryOutcomes measure: Best Overall Response Rate， BOR, secondaryOutcomes measure: PFS rate of 6 month, secondaryOutcomes measure: OS rate of 6 month, secondaryOutcomes measure: Time to Response， TTR, secondaryOutcomes measure: Time to Complete Response， TTCR, secondaryOutcomes measure: Adverse Event， AE, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University People's Hospital, city: Beijing, country: China, contacts name: Yang Liu, role: CONTACT, phone: +8613716926210, email: pkuphliuyang@bjmu.edu.cn, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06369922, orgStudyIdInfo id: STUDY00009315, briefTitle: TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence., acronym: TENSUB, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2026-06-01, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: University of Rochester, class: OTHER, descriptionModule briefSummary: This will be a double-blind randomized control trial in women with stress urinary incontinence who are undergoing an outpatient transurethral bulking procedure for stress urinary incontinence. Subjects will be identified by the University of Rochester urologists and urogynecologists participating in the study who currently oversee stress incontinence care. Subjects will be randomized into two groups. One group will be undergoing the cystoscopy with transcutaneous electrical nerve stimulation (TENS) for analgesia, and the second group will have the cystoscopy with placebo TENS., conditionsModule conditions: Stress Incontinence Female, conditions: Urinary Incontinence, conditions: Urinary Incontinence,Stress, conditions: Pain, conditions: Pain Acute, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: TENS, interventions name: Control TENS, outcomesModule primaryOutcomes measure: Mean pain measured by Visual Analog Scale (VAS), primaryOutcomes measure: Mean pain measured by Visual Analog Scale (VAS), primaryOutcomes measure: Mean pain measured by Visual Analog Scale (VAS), secondaryOutcomes measure: Mean pain measured by Likert scale, secondaryOutcomes measure: Mean pain measured by Likert scale, secondaryOutcomes measure: Mean pain measured by Likert scale, secondaryOutcomes measure: Number of participants with side effects, secondaryOutcomes measure: Mean satisfaction with the procedure, secondaryOutcomes measure: TENS or NO TENS, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pelvic Health and Continence Specialties, city: Rochester, state: New York, zip: 14623, country: United States, contacts name: Jared M Floch, DO, MS, role: CONTACT, phone: 585-895-9301, email: jared_floch@urmc.rochester.edu, contacts name: Diego Hernandez-Aranda, MD, role: CONTACT, phone: (585) 487-3400, email: diego_hernandezaranda@urmc.rochester.edu, contacts name: Jared M Floch, DO, MS, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.15478, lon: -77.61556, hasResults: False
protocolSection identificationModule nctId: NCT06369896, orgStudyIdInfo id: SpyIDUSForNonictericStricture, briefTitle: Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures, acronym: Spy+IDUS, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-05, primaryCompletionDateStruct date: 2025-12-25, completionDateStruct date: 2026-12-25, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Soonchunhyang University Hospital, class: OTHER, descriptionModule briefSummary: This study aims to evaluate the usefulness of disposable digital single-operator cholangioscopy (SOC) and intraductal ultrasound (IDUS) for the accurate diagnosis of indeterminate biliary stricture., conditionsModule conditions: Cholangiocarcinoma, conditions: Biliary Stricture, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: diagnostic accuracy of SOC, secondaryOutcomes measure: Diagnostic accuracy of IDUS, secondaryOutcomes measure: Technical success of SOC, secondaryOutcomes measure: Technical success of IDUS, secondaryOutcomes measure: Adverse event, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06369883, orgStudyIdInfo id: 2022/41, briefTitle: How Often and What Type of Deformity is Detected in All Spine Radiographs?, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-08-30, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Bakirkoy Dr. Sadi Konuk Research and Training Hospital, class: OTHER_GOV, descriptionModule briefSummary: The study will be done retrospectively.The aim of this study is to retrospectively examine the spinal pathologies of patients with a prediagnosis of spinal deformity and for whom spinal radiography is requested and to evaluate the clinical features of these patients., conditionsModule conditions: Scoliosis, conditions: Kyphosis, conditions: Radiography, designModule studyType: OBSERVATIONAL, designInfo observationalModel: ECOLOGIC_OR_COMMUNITY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 632, type: ESTIMATED, armsInterventionsModule interventions name: Spine radiography, outcomesModule primaryOutcomes measure: Who should have full spine radiographs?, secondaryOutcomes measure: We aimed to determine the frequency of kyphosis, types and percentages of scoliosis detected on the radiographs., eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06369857, orgStudyIdInfo id: PPY, briefTitle: Pectopexy for Apical Prolapse Management, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: This study was designed to evaluate the efficacy of pectopexy for treatment of apical pelvic organ prolapse at follow up at 12 months. Investigator also evaluates complications, improvement of symptoms, quality-of-life outcomes and patient satisfaction with surgery.Assessment of restoration of normal pelvic anatomy and lower urinary tract symptoms using transperineal ultrasound, conditionsModule conditions: Pelvic Organ Prolapse, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Case series study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Pectopexy, outcomesModule primaryOutcomes measure: Pelvic Organ Prolapse Quantification stage, secondaryOutcomes measure: Urinary Symptoms questionnaire, secondaryOutcomes measure: Bladder neck measurements using Transperineal US, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06369844, orgStudyIdInfo id: 1.2023-440, briefTitle: Pressure Injury Education Intervention for Pediatric Intensive Care Nurses: A Randomized Controlled Trial, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-04-03, completionDateStruct date: 2024-04-30, studyFirstPostDateStruct date: 2024-04-17, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Ankara Yildirim Beyazıt University, class: OTHER, collaborators name: Ankara City Hospital Bilkent, descriptionModule briefSummary: The purpose of this observational study is to find out the impact of pressure injury education on the knowledge level of pediatric intensive care nurses and the likelihood of pediatric pressure injury occurrence. The main questions it aims to answer are:* Does pressure injury education increase nurses knowledge level on pediatric pressure injuries?* Does the rate of pediatric pressure injuries decrease after the education?The researcher will compare nurses working in two separate pediatric intensive care units where similar patients are treated to see if planned education on pressure injuries affects nurses knowledge level and the rate of pediatric pressure injuries.* Volunteer nurses participating in the study will answer pressure injury survey questions prepared by the researcher.* Nurses in the intervention group will attend planned education sessions provided by the researcher.* Two weeks after the completion of the education sessions, all nurses in the intervention and control groups who wish to continue participating in the study will answer the pressure injury survey questions prepared by the researcher again., conditionsModule conditions: Pressure Injury Prevention, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The study design will be two-group and pretest-posttest design., primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Pressure injury education, outcomesModule primaryOutcomes measure: Stop Pressure Injuries" Education Evaluation Survey, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ankara yıldırım Beyazıt Üniversitesi, city: Ankara, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False